December 23, 2022
Video
Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.
December 23, 2022
Article
Michelle Shiller, DO, AP/CP, MGP, discusses the evolving role of HER2 as a biomarker for the treatment of patients with breast cancer and the impact of findings from the DESTINY-Breast02, DESTINY-Breast03, and DESTINY-Breast04 trials on the HER2 testing landscape.
December 07, 2022
Video
Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.
December 07, 2022
Article
Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.
December 07, 2022
Article
Trastuzumab deruxtecan demonstrated a 64% reduction in the risk of disease progression or death compared with physician's choice of treatment in patients with advanced HER2-positive unresectable and/or metastatic breast cancer who previously received ado-trastuzumab emtansine.
December 07, 2022
Video
Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.
December 05, 2022
Article
Erika P. Hamilton, MD, discusses anticipated updates from DESTINY-Breast02 and DESTINY-Breast03 that will be presented at the 2022 San Antonio Breast Cancer Symposium, how trastuzumab emtansine will fit into the armamentarium in light of the efficacy of trastuzumab deruxtecan, and additional data to expect from SABCS regarding ADCs and beyond.
November 28, 2022
Video
Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.